CPT® Code 80428

1. Indications

The growth hormone stimulation panel (CPT® Code 80428) is indicated for the evaluation of individuals who exhibit symptoms associated with low levels of human growth hormone (HGH). The following conditions may warrant the performance of this test:

• Short Stature in Children - The test is often ordered for children who are consistently smaller than their peers or when there is a sudden deceleration in growth.
• Decreased Bone Density in Adults - Adults showing signs of reduced bone density may be evaluated for potential HGH deficiency.
• Fatigue - Persistent fatigue that cannot be attributed to other causes may lead to the consideration of HGH levels.
• Poor Exercise Tolerance - Individuals experiencing difficulty in physical activities may be assessed for HGH deficiency.
• Adverse Changes in Lipid Levels - Changes in lipid metabolism, such as elevated cholesterol levels, may prompt testing for HGH levels.

2. Procedure

The procedure for the growth hormone stimulation panel involves several critical steps to ensure accurate measurement of HGH levels in response to specific stimuli. The following steps outline the process:

• Preparation - Prior to the test, the patient must fast for at least 10 hours and refrain from any exercise to ensure that baseline HGH levels are not influenced by external factors.
• Intravenous Line Insertion - A healthcare professional will insert an intravenous (IV) line, which is necessary for administering the stimulating agents and for drawing blood samples throughout the procedure.
• Baseline Blood Sample Collection - A baseline blood sample is obtained from the IV line or through a separately reportable venipuncture to measure initial HGH levels before any stimulation occurs.
• Administration of Stimulating Agent - The test involves the infusion of arginine at a dosage of 0.5 g/kg over a period of 30 minutes, or alternatively, the administration of a single oral dose of L-dopa ranging from 250 to 500 mg.
• Post-Administration Blood Sample Collection - Following the administration of the stimulating agent, additional blood samples are collected at 30-minute intervals for up to 120 minutes. These samples are taken from the IV line or through venipuncture to monitor the changes in HGH levels over time.
• Testing Method - The serum or plasma obtained from the blood samples is analyzed using a quantitative chemiluminescent immunoassay, which provides precise measurements of HGH levels in response to the stimulation.

3. Post-Procedure

After the completion of the growth hormone stimulation panel, patients may be monitored briefly to ensure there are no immediate adverse reactions to the stimulating agents. The results of the test will typically be reviewed by a healthcare provider, who will interpret the HGH levels in the context of the patient's symptoms and medical history. Depending on the findings, further evaluation or treatment may be recommended. Patients are generally advised to resume normal activities following the procedure, unless otherwise directed by their healthcare provider.